{"nctId":"NCT02509494","briefTitle":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","startDateStruct":{"date":"2015-09-30","type":"ACTUAL"},"conditions":["Ebola Virus Disease"],"count":1023,"armGroups":[{"label":"Stage 1: Active vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo"]},{"label":"Stage 2: Active vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo"]},{"label":"Stage 2: Active vaccination for children","type":"EXPERIMENTAL","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo"]},{"label":"Stage 2: Control vaccination","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: MenACWY","Biological: Placebo"]},{"label":"Stage 2: Control vaccination for children","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: MenACWY","Biological: Placebo"]}],"interventions":[{"name":"Ad26.ZEBOV","otherNames":[]},{"name":"MVA-BN-Filo","otherNames":[]},{"name":"MenACWY","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria Stage 1 and 2:\n\n* Documented community engagement from community leader and a signed inform consent form (ICF) from each participant must be available\n* Participant Stage 1 must be 18 years or older at screening and be resident in selected study community with no intention to move from study area within the next 5 months\n* Participant must be healthy with no abnormalities in laboratory screening tests within 28 days before Dose 1 vaccination\n* Female participants of childbearing potential must use adequate birth control measures and must have a negative pregnancy test at screening and immediately prior to each study vaccination\n* Participant must pass the test of understanding (TOU)\n\nAdditional Inclusion criteria Stage 2:\n\n* One year or older at screening (children of enrolled parents are eligible)\n* Parent/legal guardian (for children) must pass the TOU before signing the ICF\n* Subjects aged 7 years and older will be asked to give positive assent in the presence of a witness\n\nExclusion Criteria:\n\n* Diagnosed with EVD or under quarantine/exposed to Ebola or body temperature equal of \\>= 38 degree Celsius (fever)\n* Having an acute illness (mild in nature that can be treated at home) or any clinically significant acute/chronic medical condition or having a decreased number of red blood cells/hemoglobin in the blood (anemia)\n* Previously participated in another Ebola interventional study or received any Ad26/MVA-based candidate vaccine\n* Vaccinated with live attenuated vaccines within 30 days or with inactivated vaccines 15 days before Dose 1 vaccination\n* Treated with an immunosuppressive drug at the time of screening\n\nAdditional exclusion criteria:\n\n\\- Children up to 5 years of age with severe malnutrition (underweight or Z-score weight \\<2)","healthyVolunteers":true,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8)","description":"Number of participants with solicited local AEs were reported. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"30","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"21","spread":null},{"groupId":"OG008","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Stages 1 and 2: Number of Participants With Solicited Local AEs (Day 64)","description":"Number of participants with solicited local AEs were reported. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"21","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"22","spread":null},{"groupId":"OG006","value":"5","spread":null},{"groupId":"OG007","value":"7","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 1: Number of Participants With Solicited Local AEs (Day 738)","description":"Number of participants with solicited local AEs were reported. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 8)","description":"Number of participants with solicited systemic AEs were reported. Solicited systemic AEs included body temperature, vomiting, reduced activity, somnolence, fatigue, irritability/fussiness/crying/screaming, and loss of appetite (for preverbal children/infants) and body temperature, nausea/vomiting, fatigue/malaise, muscle pain, chills, joint pain and headache (for young children, adolescents, and adults).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"161","spread":null},{"groupId":"OG002","value":"51","spread":null},{"groupId":"OG003","value":"52","spread":null},{"groupId":"OG004","value":"14","spread":null},{"groupId":"OG005","value":"45","spread":null},{"groupId":"OG006","value":"15","spread":null},{"groupId":"OG007","value":"36","spread":null},{"groupId":"OG008","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 64)","description":"Number of participants with solicited systemic AEs were reported. Solicited systemic AEs included body temperature, vomiting, reduced activity, somnolence, fatigue, irritability/fussiness/crying/screaming, and loss of appetite (for preverbal children/infants) and body temperature, nausea/vomiting, fatigue/malaise, muscle pain, chills, joint pain and headache (for young children, adolescents, and adults).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"26","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"27","spread":null},{"groupId":"OG006","value":"8","spread":null},{"groupId":"OG007","value":"23","spread":null},{"groupId":"OG008","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 1: Number of Participants With Solicited Systemic AEs (Day 738)","description":"Number of participants with solicited systemic AEs were reported. Solicited systemic AEs included body temperature, vomiting, reduced activity, somnolence, fatigue, irritability/fussiness/crying/screaming, and loss of appetite (for preverbal children/infants) and body temperature, nausea/vomiting, fatigue/malaise, muscle pain, chills, joint pain and headache (for young children, adolescents, and adults).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"PRIMARY","title":"Stages 1: Number of Participants With Serious Adverse Events (SAEs)","description":"Number of Participants with SAEs were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Stages 2: Number of Participants With SAEs","description":"Number of Participants with SAEs were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"15","spread":null},{"groupId":"OG007","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 1: Number of Participants With Unsolicited AEs (Day 759)","description":"Number of participants with unsolicited AEs were reported. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 1: Number of Participants With Unsolicited AEs (Day 29)","description":"Number of participants with unsolicited AEs were reported. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 2: Number of Participants With Unsolicited AEs (Day 29)","description":"Number of participants with unsolicited AEs were reported. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"60","spread":null},{"groupId":"OG005","value":"18","spread":null},{"groupId":"OG006","value":"88","spread":null},{"groupId":"OG007","value":"28","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 1: Number of Participants With Unsolicited AEs (Day 85)","description":"Number of participants with unsolicited AEs were reported. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 2: Number of Participants With Unsolicited AEs (Day 85)","description":"Number of participants with unsolicited AEs were reported. Unsolicited AEs were all AEs for which the participant is not specifically questioned in the participant diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"46","spread":null},{"groupId":"OG005","value":"13","spread":null},{"groupId":"OG006","value":"92","spread":null},{"groupId":"OG007","value":"31","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 1: Number of Participants With Deaths","description":"Number of participants with deaths were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 2: Number of Participants With Deaths (Children and Adolescents)","description":"Number of participants (children and adolescents) with deaths were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 2: Number of Participants With Deaths (Adults)","description":"Number of participants (adults) with deaths were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 1: Number of Participants With Immediate Reportable Event (IREs)","description":"Number of participants with IREs were reported. The following list of neuroinflammatory disorders are categorized as IREs: Cranial nerve disorders, including paralyses/paresis, optic neuritis, multiple sclerosis, transverse myelitis, guillain-Barré syndrome, acute disseminated encephalomyelitis, including site specific variants, myasthenia gravis and Lambert-Eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, narcolepsy, isolated paresthesia of greater than (\\>) 7 days duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 2: Number of Participants With IREs (Children and Adolescents)","description":"Number of participants (children and adolescents) with IREs were reported. The following list of neuroinflammatory disorders are categorized as IREs: Cranial nerve disorders, including paralyses/paresis, optic neuritis, multiple sclerosis, transverse myelitis, guillain-Barré syndrome, acute disseminated encephalomyelitis, including site specific variants, myasthenia gravis and Lambert-Eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, narcolepsy, isolated paresthesia of greater than (\\>) 7 days duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Stage 2: Number of Participants With IREs (Adults)","description":"Number of participants (adults) with IREs were reported. The following list of neuroinflammatory disorders are categorized as IREs: Cranial nerve disorders, including paralyses/paresis, optic neuritis, multiple sclerosis, transverse myelitis, guillain-Barré syndrome, acute disseminated encephalomyelitis, including site specific variants, myasthenia gravis and Lambert-Eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, narcolepsy, isolated paresthesia of greater than (\\>) 7 days duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Stages 1 and 2: Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Enzyme-linked Immunosorbent Assay (ELISA)","description":"GMCs of antibodies binding to EBOV GP using ELISA were reported and were measured in ELISA units per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4784","spread":null},{"groupId":"OG001","value":"3810","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"9929","spread":null},{"groupId":"OG004","value":"74","spread":null},{"groupId":"OG005","value":"10212","spread":null},{"groupId":"OG006","value":"42","spread":null},{"groupId":"OG007","value":"22568","spread":null},{"groupId":"OG008","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":43},"commonTop":["Malaria","Headache","Upper Respiratory Tract Infection","Respiratory Tract Infection","Nasopharyngitis"]}}}